Why do men get prostate cancer?

The answer to this question, some 70 to 80 years after we started to see if we could answer it, is still: “We haven’t got a clue.” But every so often people come up with a new or a revised hypothesis, and it can take years to work out whether each specific hypothesis is viable. … READ MORE …

The importance of listening to patients

A report yesterday on on the MedPage Today web site quotes Scott Gottlieb, MD, the Commissioner of the U.S. Food & Drug Administration (FDA) on the importance of “Listening to patients” and on how patients’ perspectives can inform drug development, drug review, and physicians’ prescribing habits. … READ MORE …

What is “Prostac” and where can you get it?

Someone asked the sitemaster yesterday about a new test for risk of prostate cancer called Prostac® and where he could access this. … READ MORE …

Minnelide: a possible new drug for the treatment of CRPC?

According to a recently published article in The Prostate, researchers at the University of Minnesota have developed a new type of drug that they believe may have high therapeutic potential in the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …

“Competitive analysis” in the development of drugs for advanced prostate cancer

So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …

The history of the clinical trials process

Readers with an interest in how we got to today’s clinical trials processes for evaluating new drugs for the treatment of prostate cancer and other diseases might be surprised by what’s in an article in this week’s New England Journal of Medicine. … READ MORE …

Effective, safe, and as fast as reasonably possible

For readers who are interested in the processes and the speed with which potential new cancer drugs can be brought to market here in the USA (and other places around the world too), there in an important article in this week’s New England Journal of Medicine. … READ MORE …